Overview

Cyclic Vomiting: Droperidol

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to compare two commonly used agents for the treatment of cyclic vomiting to see if one agent is inferior to the other in time to improvement in symptoms, need for repeat or rescue medications, treatment failures and complications/side effects.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Spectrum Health - Lakeland
Treatments:
Droperidol
Haloperidol
Haloperidol decanoate
Criteria
Inclusion Criteria:

- adult patients with clinical diagnosis of cyclic vomiting in the ED

Exclusion Criteria:

- pregnancy, allergy to any of the study medicines